Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| 0.668 | |
| 0.6681 | |
| - | |
| 0.6751 | |
| 0.6501 | |
| 0.538-2.28 | |
| 47 925 K | |
| 72 801 K | |
| 7 000 K | |
| -0.3 | |
| 0.275 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we will take a look at the 13 best penny stocks to buy according to billionaire Ken Griffin. To see more such companies, go directly to 5 Best Penny Stocks to Buy According to Billion...
In this article, we will take a look at the 12 best penny stocks to buy under $1. To see more such companies, go directly to 5 Best Penny Stocks to Buy Under $1. Investors are optimistic as we move i...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
